XDx Announces Highmark's Coverage of AlloMap(R) for Monitoring Heart ... MarketWatch (press release) Highmark considers AlloMap "medically necessary" for monitoring heart transplant rejection, recognizing the clinical benefits of a non-invasive method for managing rejection in stable heart transplant recipients. AlloMap now is covered for ... |
